PuSH - Publication Server of Helmholtz Zentrum München: A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer.

Information

Clues to quality of journals

Open Access Policy of Helmholtz Association 2016

CC Licencences

Publication Metrics

Navigation

Home

Deutsch

EVA: Electronic Publishing

New EVA Application

Research

Advanced Search

Browse by ...

... HMGU-Authors/Consortia

... Organizational Structure

... Journal

... Publication Type

... Research Data

... Arbeitsgruppen

... Publication Year

Publication overview

Statistics

Statistics (last 5 years)

OA Publications

Publish

Submit Publication

Import publication from...

...EVA

Report missing publication

Highlights

Support & Contact

Contact persons

Help

Data protection

Helmholtz Open Science

JANE Journal Estimator

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Schönhuber, N.* ; Seidler, B.* ; Schuck, K.* ; Veltkamp, C.* ; Schachtler, C.* ; Zukowska, M.* ; Eser, S.* ; Feyerabend, T.B.* ; Paul, M.C.* ; Eser, P.* ; Klein, S.* ; Lowy, A.M.* ; Banerjee, R.* ; Yang, F.* ; Lee, C.L.* ; Moding, E.J.* ; Kirsch, D.G.* ; Scheideler, A. ; Alessi, D.R.* ; Varela, I.* ; Bradley, A.* ; Kind, A.* ; Schnieke, A.E.* ; Rodewald, H.R.* ; Rad, R.* ; Schmid, R.M.* ; Schneider, G.* ; Saur, D.*

A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer.

Nat. Med. 20, 1340-1347 (2014)

DOI

PMC

Open Access Green as soon as Postprint is submitted to ZB.

Abstract
Metrics
Extra information

Genetically engineered mouse models (GEMMs) have dramatically improved our understanding of tumor evolution and therapeutic resistance. However, sequential genetic manipulation of gene expression and targeting of the host is almost impossible using conventional Cre-loxP-based models. We have developed an inducible dual-recombinase system by combining flippase-FRT (Flp-FRT) and Cre-loxP recombination technologies to improve GEMMs of pancreatic cancer. This enables investigation of multistep carcinogenesis, genetic manipulation of tumor subpopulations (such as cancer stem cells), selective targeting of the tumor microenvironment and genetic validation of therapeutic targets in autochthonous tumors on a genome-wide scale. As a proof of concept, we performed tumor cell-autonomous and nonautonomous targeting, recapitulated hallmarks of human multistep carcinogenesis, validated genetic therapy by 3-phosphoinositide-dependent protein kinase inactivation as well as cancer cell depletion and show that mast cells in the tumor microenvironment, which had been thought to be key oncogenic players, are dispensable for tumor formation.

Impact Factor

Scopus SNIP

Web of Science
Times Cited

Scopus
Cited By

Altmetric

28.054

4.705

127

146